The Bull Case For ACADIA Pharmaceuticals (ACAD) Could Change Following EMA Setback For Trofinetide Approval [Yahoo! Finance]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Yahoo! Finance
issued a negative trend vote on its Marketing Authorization Application for trofinetide to treat Rett syndrome, with Acadia planning to pursue a formal re-examination if the opinion is adopted. This setback underscores how critical European regulatory decisions are for expanding access to trofinetide beyond its existing approvals in the United States, Canada, and Israel. We'll now examine how this negative CHMP trend vote on trofinetide shapes Acadia Pharmaceuticals' investment narrative and future growth opportunities. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. To own Acadia Pharmaceuticals today, you need to believe in the durability of its existing neurology franchise and its ability to turn a focused rare-disease pipeline into incremental, not just binary, upside. The CHMP's negative trend vote for trofinetide in Rett syndrome complicates one of the nearer-te
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- Exploring US High Growth Tech Stocks This February 2026 [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals' Rett Syndrome Medication Less Likely to Receive EU Approval, RBC Says [Yahoo! Finance]Yahoo! Finance
- ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $31.00 price target on by analysts at Royal Bank Of Canada.MarketBeat
- ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "market outperform" rating reaffirmed by analysts at Citizens Jmp. They now have a $34.00 price target on the stock.MarketBeat
- ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $37.00 price target on the stock.MarketBeat
ACAD
Earnings
- 11/5/25 - Beat
ACAD
Sec Filings
- 1/13/26 - Form 8-K
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- ACAD's page on the SEC website